Short Interest in Genfit S.A. (NASDAQ:GNFT) Declines By 40.5%

Genfit S.A. (NASDAQ:GNFT) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 60,300 shares, a decrease of 40.5% from the January 31st total of 101,300 shares. Based on an average daily volume of 8,400 shares, the short-interest ratio is presently 7.2 days. Currently, 0.1% of the company’s stock are sold short.

Genfit Stock Performance

NASDAQ:GNFT traded up $0.07 on Tuesday, hitting $3.47. The company’s stock had a trading volume of 16,612 shares, compared to its average volume of 8,895. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. The stock has a fifty day moving average of $3.73 and a two-hundred day moving average of $4.40. Genfit has a one year low of $3.35 and a one year high of $6.42.

Institutional Trading of Genfit

An institutional investor recently bought a new position in Genfit stock. Millennium Management LLC acquired a new stake in Genfit S.A. (NASDAQ:GNFT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned 0.33% of Genfit as of its most recent SEC filing. Institutional investors own 2.24% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Genfit in a research report on Friday, February 7th.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.